Erratum to: phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion
© Hamilton et al.; licensee BioMed Central Ltd. 2013
Received: 26 March 2013
Accepted: 26 March 2013
Published: 27 March 2013
The Research to this article has been published in Journal of Translational Medicine 2012 10:28
In our original manuscript , the corresponding author, Michael A Morse, was missed from the authors’ list. Therefore the correct author list should be:
Erika Hamilton, Kimberly Blackwell, Amy C Hobeika, Timothy M Clay, Gloria Broadwater, Xiu-Rong Ren, Wei Chen, Henry Castro, Frederic Lehmann, Neil Spector, Junping Wei, Takuya Osada, H Kim Lyerly and Michael A Morse.
Also the title of our original manuscript ‘Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion’ is also incorrect. The title should read:‘Phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibition’.
Journal of Translational Medicine regret any inconvenience that this inaccuracy might have caused.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.